Search Patents
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20220332765
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: March 22, 2022
    Publication date: October 20, 2022
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20230070886
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: January 27, 2021
    Publication date: March 9, 2023
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20220125914
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: January 10, 2022
    Publication date: April 28, 2022
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • Coronavirus vaccine
    Patent number: 11547673
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: January 10, 2023
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20240165221
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 23, 2024
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • POLYPEPTIDE VACCINE COUPLED WITH TLR7 AGONIST FOR NOVEL CORONAVIRUS AND USE THEREOF
    Publication number: 20230241204
    Abstract: Disclosed are a polypeptide vaccine coupled with a TLR7 agonist for novel coronavirus and the use thereof. Specifically, the present invention provides a vaccine polypeptide for novel coronavirus pneumonia based on the basis of the analytical study of the RBD sequence and structural information of the S protein of SARS-CoV-2, wherein the vaccine polypeptide has the following structural formula: Z-(J-U)n, where in the formula, Z, J, U, n, etc. are as defined in the description. Also provided in the present invention are a vaccine composition containing the vaccine polypeptide and the use thereof.
    Type: Application
    Filed: December 1, 2020
    Publication date: August 3, 2023
    Inventors: Likun GONG, Jin REN, Guangyi JIN, Wei HUANG, Qiuping QIN, Yiru LONG, Jianhua SUN, Tingting LIU, Feng TANG, Peng ZHU
  • Coronavirus vaccine formulations
    Patent number: 11253586
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: February 22, 2022
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • Coronavirus vaccine formulations
    Patent number: 10953089
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: March 23, 2021
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • Nucleic acid vaccines for coronavirus
    Patent number: 11510977
    Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: November 29, 2022
    Assignee: Suzhou Abogen Biosciences Co., Ltd.
    Inventor: Bo Ying
  • Coronavirus vaccine
    Patent number: 11925694
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 12, 2024
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • Coronavirus vaccine formulations
    Patent number: 11541112
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: January 3, 2023
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION
    Publication number: 20210261644
    Abstract: Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 26, 2021
    Inventors: Zhiwei Chen, Kwok Yung Yuen, Honglin Chen, Yik Chun Wong, Li Liu
  • VACCINE COMPOSITION FOR PREVENTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION
    Publication number: 20230272015
    Abstract: The present invention relates to a vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection. The vaccine composition for preventing severe acute respiratory syndrome coronavirus 2 infection according to the present invention comprises spike and ORF3a or nucleocapsid as an antigen against SARS-CoV-2. The vaccine composition has a significant effect of inducing antibody immune responses and T-cell immune responses by a plurality of co-expressed antigens compared to those comprising one antigen, and thus can be variously used in the field of prevention of severe acute respiratory syndrome coronavirus 2 infection.
    Type: Application
    Filed: July 19, 2021
    Publication date: August 31, 2023
    Inventors: Young Keun Park, Byung Mun Cho, Moon Sup Jeong, Hyo Jin Lee, Song Yion Yeu, Young Ran Cho, Bo Yeong Park, Areum Gil, Bo Hyun Jeon, Ye Eun Oh, Gee Ho Park, Joel Maslow, Christine Claire Roberts, Mi Young KIM, Jung Ah Lee, Hee Ji Lim, Yun Ho Hwang
  • Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
    Publication number: 20230355741
    Abstract: The present invention provides new vaccines for felines and ferrets to aid in reducing shedding of severe acute respiratory syndrome coronavirus 2 by infected felines or ferrets. Methods of making and using the vaccines alone or in combinations with other protective agents are also provided.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 9, 2023
    Applicant: Intervet Inc.
    Inventors: Mark A. Mogler, Ian Tarpey
  • ADJUVANTS FOR SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS (SARS-COV) VACCINES
    Publication number: 20230201340
    Abstract: Provided herein are adjuvantation systems for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus antigen.
    Type: Application
    Filed: May 28, 2021
    Publication date: June 29, 2023
    Applicant: Children's Medical Center Corporation
    Inventors: David J. Dowling, Ofer Levy, Francesco Borriello, Etsuro Nanishi, Timothy O'Meara, Yoshine Saito, Simon D. van Haren
  • Adjuvants for vaccines
    Patent number: 5047238
    Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
    Type: Grant
    Filed: March 24, 1988
    Date of Patent: September 10, 1991
    Assignee: American Home Products Corporation
    Inventors: William M. Acree, Bobby Edwards, John W. Black
  • Inactivation of Genome Enveloped within Coronavirus Spherical or Pleomorphic Particles or Shells to Form a Vaccine
    Publication number: 20230226172
    Abstract: Vaccine based on ethanol inactivated pathogens, or part thereof, are described herein. Also disclosed are certain vaccines for treating COVID-19 or other coronavirus related diseases is created by deactivating the genome, genetic material or RNA encapsulated within the shell of virus without eliminating the spikes or spike protein, which both attaches the virus to a host cell and is detected by the body to produce antibodies. Treatment of an active coronavirus with a material such as an effective amount of ethanol will both penetrate the shell and deactivate the genetic material which causes the disease, for preparation of a vaccine.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 20, 2023
    Inventors: Schossau M. Tom, Kurup K. Shree, Schossau Jorden
  • Adenovirus-Based SARS-CoV-2 Vaccine
    Publication number: 20230241202
    Abstract: A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided along with a method of generating and anti-coronavirus immune response. A microneedle array is provided, along with methods of making and using the microneedle array.
    Type: Application
    Filed: May 28, 2021
    Publication date: August 3, 2023
    Inventors: Andrea A. Gambotto, Louis Falo, Jr., Eun Kim
  • CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST
    Publication number: 20230110516
    Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
    Type: Application
    Filed: March 1, 2021
    Publication date: April 13, 2023
    Applicants: Dynavax Technologies Corporation, MEDIGEN VACCINE BIOLOGICS CORPORATION
    Inventors: John D. CAMPBELL, Robert S. JANSSEN, David NOVACK, Tsun-Yung KUO, Charles CHEN, Chung-Chin WU, Yi-Jiun LIN, Meei-Yun LIN, Yu-Chi WU
  • NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS
    Publication number: 20240024462
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Application
    Filed: September 12, 2023
    Publication date: January 25, 2024
    Inventors: Etienne SIMON-LORIERE, Matthieu PROT, Xavier MONTAGUTELLI
Narrow Results

Filter by US Classification